Aprecia offers the ZipDose product platform using three-dimensional printing (3DP) technology to create fast-melt products. The company has completed clinical development and expects to file its first NDA with the FDA in 2H14. inVentiv will serve as Aprecia’s exclusive provider of commercialization services in exchange for future royalties on sales.
“Getting medicine into the human body reliably and accurately is both a challenge and an enormous opportunity,” said Don Wetherhold, chief executive officer of Aprecia. “To realize the potential of our technology and move quickly into market, we sought a partner that could execute every phase and function in commercialization, and inVentiv was the obvious choice.”
Michael Griffith, executive vice president of inVentiv Health, said, “We are pleased to have entered into this agreement with Aprecia and are looking forward to introducing their innovative technology platform and their much-needed products. Because of our unmatched expertise of pharmaceutical launches, clients know they can count on inVentiv Health to transform their assets into commercial success.”